{
    "nctId": "NCT00060320",
    "briefTitle": "Black Cohosh in Treating Hot Flashes in Women Who Have or Who Are At Risk of Developing Breast Cancer",
    "officialTitle": "A Phase III Double-Blind, Randomized, Placebo-Controlled Crossover Trial Of Black Cohosh In The Management Of Hot Flashes",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Hot Flashes",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 132,
    "primaryOutcomeMeasure": "Hot flash activity",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* History of breast cancer OR concern about taking hormones because of fear of breast cancer\n\n  * No current active disease\n  * No current evidence of malignant disease\n* Bothersome hot flashes\n\n  * Patient-reported occurrence at least 14 times per week and of sufficient severity to make the patient desire therapeutic intervention\n* Hormone receptor status:\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 18 and over\n\nSex\n\n* Female\n\nPerformance status\n\n* ECOG 0-1\n\nLife expectancy\n\n* At least 6 months\n\nOther\n\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* Able to complete questionnaires alone or with assistance\n\nPRIOR CONCURRENT THERAPY:\n\nChemotherapy\n\n* More than 4 weeks since prior antineoplastic chemotherapy\n* No concurrent antineoplastic chemotherapy during the double-blind portion of the study\n\nEndocrine therapy\n\n* More than 4 weeks since prior androgens, estrogens, or progestational agents\n* More than 2 weeks since prior dehydroepiandrosterone (DHEA) for hot flashes\n* No concurrent androgens, estrogens, or progestational agents during the double-blind portion of the study\n* No concurrent DHEA for hot flashes\n* Concurrent tamoxifen, raloxifene, or an aromatase inhibitor is allowed provided the patient started the drug at least 4 weeks prior to study entry and plans to continue the drug throughout the double-blind portion of the study Other\n* More than 2 weeks since prior antidepressants\n* More than 2 weeks since other prior agents for treating hot flashes (e.g., clonidine or Bellergal-s)\n* No prior black cohosh\n* No concurrent antidepressants during the double-blind portion of the study\n* No other concurrent agents for treating hot flashes (e.g., clonidine or Bellergal-s)\n\n  * Concurrent vitamin E and/or soy allowed provided patient is on a stable dose for at least 1 month prior to study entry and plans to continue the same dose throughout study duration\n* No concurrent oral herbal therapies or therapeutic herbal teas or tinctures except beverage teas (e.g., chamomile, ginger, peppermint, lemongrass, and fruit-based tea)",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}